Latest news with #AgilusDiagnostics
Time of India
15-07-2025
- Health
- Time of India
Agilus launches new antibody test for diagnosing arthritis
New Delhi: Agilus Diagnostics , in collaboration with Sebia , has launched an Anti-MCV (anti–mutated citrullinated vimentin) antibody test that provides early detection of rheumatoid arthritis (RA). Developed by Sebia, the new antibody test enhances the early detection of rheumatoid arthritis (RA), especially in patients who test negative for conventional markers like anti-CCP and rheumatoid factor (RF). 'Studies show that 10–15 per cent of RA cases missed by anti-CCP can be picked up through anti-MCV testing. When patients present with persistent symptoms but test negative for both CCP and RF, anti-MCV offers clinicians a valuable next step,' a statement from the company spokesperson reads. The new antibody test is a highly sensitive and specific biomarker, which detects autoantibodies against a mutated form of the vimentin protein particularly valuable for identifying RA in individuals who test negative for conventional markers such as anti-CCP and rheumatoid factor (RF), the company said. Clinical data also supports the combined use of anti-MCV and anti-CCP to enhance diagnostic accuracy. When used together, these tests can increase sensitivity without compromising specificity, helping to identify RA in its earliest stages, when therapeutic intervention can make the greatest difference, it added.
&w=3840&q=100)
Business Standard
27-06-2025
- Health
- Business Standard
Genomic testing sees sharp uptake in India, now growing beyond metros
With 18 per cent CAGR, India's genomic diagnostics market is expanding into Tier 2 and 3 cities as affordability, cancer screening, and personalised care fuel adoption Anjali Singh Mumbai Demand for genomic testing in India has surged significantly over the past two to three years, fuelled by growing clinical awareness, rapid technological advancements and the rising adoption of personalised medicine. From being a niche service concentrated in major metros, genomic diagnostics are now expanding into Tier 2 and Tier 3 cities, reshaping the landscape of preventive and precision healthcare. The Indian genomic diagnostics market is valued at $550 million in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 18 per cent, reaching $2,066.31 million by 2030, according to industry estimates. Key drivers include wider physician adoption, declining test prices, improved accessibility and a shift in consumer behaviour towards proactive and personalised healthcare. Diagnostic majors such as Agilus Diagnostics, Metropolis Healthcare, Dr Lal PathLabs, Mahajan Imaging and Labs, and Redcliffe Labs report double-digit growth in the segment. While metros like Mumbai, Bengaluru and Delhi still contribute the lion's share, growing awareness and infrastructure in cities like Lucknow, Bhubaneswar, Pune, Kochi and Surat are driving demand beyond urban hubs. Test affordability has improved substantially. Prices for routine genomic tests—like BRCA1/2 (used to analyse a person's DNA to identify mutations in genes that increase the risk of breast and ovarian cancer) and NIPT (non-invasive prenatal testing, a blood test performed on pregnant women to assess the risk of certain genetic conditions in the foetus)—have come down by 30–40 per cent, now ranging between Rs 5,000 and Rs 20,000, depending on complexity. While advanced oncology panels and exome sequencing can still cost up to Rs 2 lakh, widespread adoption of high-throughput platforms and in-house test development has made even complex testing more accessible. Experts believe that although demand for genomic testing is rising across multiple segments, increasing cancer incidence and a countrywide focus on cancer detection and reproductive health have been key growth drivers. 'The rapid increase in demand for cancer tests, along with paediatric and reproductive health applications like prenatal testing and carrier testing, are major contributing factors driving growth in genetic testing. The country is also witnessing a rise in testing for rare genetic diseases, driven by India's huge genetic diversity,' said Nilaya Varma, group chief executive officer and co-founder, Primus Partners. 'Genomic testing now contributes 5–7 per cent of our total diagnostics revenue, up from under 2 per cent three years ago,' said Anand K, managing director and chief executive officer, Agilus Diagnostics. Redcliffe Labs pegs this number even higher, at 30–40 per cent, with consistent 20 per cent year-on-year growth in test volumes. 'We've seen a dramatic rise in genomic testing demand over the past five years, especially in oncology, rare diseases and reproductive health. What's encouraging is that Tier 2 and 3 cities like Lucknow, Bhubaneswar and Coimbatore are now actively adopting these tests,' said Himani Pandey, lab head – genomics, Redcliffe Labs. Metropolis Healthcare, which entered the genomics space three years ago, has seen over 50 per cent revenue growth in the segment and plans further expansion through investments in bioinformatics and next-generation sequencing (NGS) platforms. 'We've seen over 50 per cent revenue growth in genomics since our entry into the space three years ago. Genomic testing is increasingly being integrated into routine health check-ups, cancer diagnostics, rare disease screening and personalised treatment planning. We are investing heavily in bioinformatics and NGS platforms to scale further,' said Kirti Chadha, chief scientific and innovation officer, Metropolis Healthcare. Similarly, Dr Lal PathLabs, through its genomics division Genevolve, has launched over 500 tests covering oncogenomics, neurogenomics, rare disease panels and reproductive health. 'With Illumina's NovaSeq X platform at our national reference lab and a focused genomics sales team, we're bringing cutting-edge testing to both metros and smaller towns,' said Shankha Banerjee, chief executive officer, Dr Lal PathLabs. While margins on genomic tests can vary—and in many cases remain lower than routine diagnostics due to high input costs and low volumes—players see genomics as a long-term strategic bet. 'It's not just about margins—it's about clinical value and helping doctors make better treatment decisions,' said Shelly Mahajan, lab director at Mahajan Imaging. A common thread across players is the push for in-house development and Indian population–specific panels, often coupled with global partnerships for specialised tests. Most labs are also investing in AI-driven bioinformatics, advanced molecular labs and automation to enhance scalability. Yet, challenges remain. Despite cost reductions, insurance coverage for genomic tests in India is still extremely limited, creating affordability barriers for patients in lower-income segments. Industry leaders stress that broader insurance inclusion could accelerate adoption, particularly for cancer, rare diseases and reproductive health-related tests. Nonetheless, the momentum is clear: Genomic testing is no longer a fringe offering. With its ability to provide deep molecular insights for early diagnosis, targeted therapy and risk prediction, it is fast becoming a core pillar in India's diagnostics growth strategy.
Mint
10-06-2025
- Health
- Mint
What's causing low AMH levels in Indian women?
Doctors in fertility clinics across India—from buzzing metros to smaller tier-2 and tier-3 cities— are observing a startling pattern: a significant number of young women, even those in their late twenties and early thirties, are presenting with alarmingly low anti-Müllerian hormone (AMH) levels, a key marker of ovarian reserve. This phenomenon, once primarily associated with women in their 40s, now appears to be afflicting women a decade earlier, quietly reshaping the reproductive health landscape of the country. Also read: What you should know about freezing your eggs 'We're seeing a clear downward trend in AMH levels even among women under 35," says Dr Rita Modi, senior IVF consultant at Motherhood Fertility & IVF, Kharghar, Navi Mumbai. 'And it's no longer restricted to urban India. The trend is equally concerning in smaller towns." AMH, a hormone secreted by cells in developing ovarian follicles, is a critical indicator of a woman's egg supply. A drop in this value suggests a diminished ovarian reserve, reducing the chances of natural conception and often foreshadowing challenges with assisted reproductive techniques as well. Dr Angeli Misra, director of Lifeline Laboratory, Agilus Diagnostics in Delhi, confirms this trend with empirical data: 'The total number of AMH tests conducted pan-India in our centres annually is 4,700. There is definitely a noticeable rise in AMH tests being done in women under 35. This trend is mainly seen in metros and among young professionals who are starting their careers." THE AGEING OVARY PARADOX Paradoxically, this crisis comes at a time when India—still home to the world's largest population—is witnessing a declining total fertility rate (TFR). According to data from the National Family Health Survey, India's TFR dropped from 2.2 children per woman in 2015–16 to 2.0, slipping below the replacement level of 2.1. This reflects significant strides in maternal health and contraceptive awareness, but it also masks an emerging challenge: the premature biological ageing of Indian ovaries. 'Indian women typically hit menopause five years earlier than their Western counterparts," explains Dr Sonia Malik, chief clinical mentor at Nova IVF Fertility. 'It's not just social delay in motherhood—there's a deeper genetic and epigenetic acceleration in ovarian ageing that we're still trying to fully understand." Malik adds that environmental and lifestyle stressors—such as urban pollution, endocrine-disrupting chemicals in cosmetics and food packaging, and the rise of processed diets may be exacerbating the issue. Also read: A practical guide to help you cut back on processed foods According to Misra, the concern is far from anecdotal. 'The percentage of women showing lower AMH levels in our laboratory is as high as 38%, and those with very low ovarian reserve is about 26%. An increasing number of women under 35 are showing a low reserve, and these numbers are increasing every year. However, one must remember that we are mainly testing women who are being investigated for infertility, and not a normal cross-section." EXTERNAL CAUSES While age and genetics remain immutable drivers, external factors are proving equally detrimental. Air and water pollution, exposure to pesticides, and endocrine disruptors—present in plastics, cosmetics, and even produce—are widely believed to interfere with hormonal signalling and damage ovarian follicles. In rural regions, infections such as genital tuberculosis, HIV, and other sexually transmitted infections are an added risk, often going undiagnosed and leading to pelvic inflammatory disease—a condition that can impair fertility by damaging the reproductive tract. 'Fertility health is increasingly under siege from both modern lifestyle choices and deep-rooted public health challenges," Modi notes. Though often sidelined, psychological stress too is proving to be a silent saboteur. Chronic stress elevates cortisol—the body's stress hormone—which disrupts the delicate hormonal balance essential for ovulation. Malik points to the 'gut-brain-reproduction axis"—a triad that, when compromised by anxiety, poor sleep, and restrictive diets, can derail reproductive function. 'Many young women with intense work cultures or disordered eating habits end up with irregular cycles or unexplained infertility. These aren't just lifestyle issues they're medical ones," she emphasizes. IS EARLY TESTING NECESSARY? With fertility clinics becoming more mainstream and technologies like egg freezing gaining popularity, there's a growing call to integrate AMH assessments into preventive health check-ups much like regular screenings for thyroid, cholesterol, or diabetes. 'AMH testing can empower women to make proactive choices about their reproductive futures," says Modi. 'But it must be done with nuance and medical oversight. We don't want to create panic or rush women into interventions they may not need." Dr Nidhi Rajotia, unit head – obstetrics and gynaecology at Artemis Hospitals, Gurgaon agrees. 'It's totally understandable for women to feel a surge of panic when they discover their AMH levels are low. It is important to keep in mind that this doesn't automatically rule out the possibility of pregnancy." AMH, Rajotia points out, is just one part of the bigger picture when it comes to assessing a woman's ovarian reserve. 'It tells us about the number of eggs, not the quality. Fertility is affected by a range of factors, such as age, egg quality, overall health, and even the health of your partner's sperm. So, having a low AMH level doesn't mean that natural conception is impossible," she explains. Also read: Planning pregnancy after 35? Here's what you should know There is also increasing curiosity around when to get tested. 'Understanding when to check your AMH levels can really help you make informed choices about your fertility," Rajotia adds. 'While there aren't any clear symptoms of low AMH, women who experience irregular periods, have a family history of early menopause, or struggle with conceiving should think about getting tested. It is also helpful for those who are planning to delay pregnancy or are considering egg freezing." Misra reinforces this sentiment by saying that there is a lot of increase in the awareness regarding the utility of AMH. 'Most women are getting it done on medical advice for investigation into infertility. However, there is an increasing number of young women who are now, as a part of their life planning—both personally and professionally—getting the test done to know their ovarian reserve and plan their future pregnancy or egg freezing," she adds. Both experts agree that fertility awareness should be part of school and college curriculums, not just restricted to biology textbooks but as part of practical health literacy. Rajotia puts it plainly: 'Education about AMH is incredibly important, not just for women dealing with fertility challenges, but for all women out there. Understanding AMH is key to becoming more aware of your reproductive health, allowing you to plan for the future with confidence." GET YOUR BASICS RIGHT Dr Parul Prakash, head, reproductive medicine (Unit I), Artemis Hospitals, Gurgaon answers basic questions on the anti-Müllerian hormone (AMH). What is AMH? AMH is produced by small follicles in the ovaries. A blood test measures AMH levels to assess the number of eggs remaining. Because AMH remains stable throughout the menstrual cycle, it is considered a reliable fertility marker. Is it normal for AMH to decline with age? Yes. AMH peaks in the mid-20s and gradually declines. By 35, the average AMH is 1.5 ng/mL (nanograms per milliliter), and by 40, it dips to around 1.0 ng/mL. Levels below 1.0 suggest a diminished reserve but don't automatically imply infertility. Why do Indian women's ovaries age faster? Studies suggest Indian women experience menopause nearly six years earlier than their Western counterparts. Factors may include genetics, environmental stressors, and lifestyle habits. Can lifestyle changes help? While we can't reverse aging, lifestyle adjustments—balanced diet, exercise, stress management, and reducing toxin exposure—can support reproductive health. Tanisha Saxena is a Delhi-based independent journalist. She writes stories that are on the intersection of art, culture and lifestyle. Also read: Magnesium mania: Understanding the hype behind the wellness trend
&w=3840&q=100)
Business Standard
20-05-2025
- Business
- Business Standard
Fortis Healthcare Q4 profit drops 7% on rise in quarterly expenses
Delhi-headquartered hospital chain Fortis Healthcare on Tuesday reported a 7.4 per cent year-on-year (Y-o-Y) fall in consolidated net profit for the March quarter of financial year 2024–25 (Q4 FY25) at Rs 188.02 crore, down from Rs 203.14 crore in the same period last year. The decline in net profit was attributed to a 13.6 per cent Y-o-Y rise in total expenses, which stood at Rs 1,741.52 crore, up from Rs 1,531.76 crore. The company also cited impairments on investments in an associate firm and assets in a subsidiary, according to its regulatory filing. Revenue from operations rose to Rs 2,007 crore in Q4 FY25, marking a 12.4 per cent increase from Rs 1,786 crore in Q4 FY24. Consolidated earnings before interest, tax, depreciation, and amortisation (EBITDA) rose 14.3 per cent Y-o-Y to Rs 435 crore, with the EBITDA margin at 21.7 per cent, up from 21.3 per cent in the year-ago period. The hospital business posted a 14.2 per cent Y-o-Y revenue increase in Q4 FY25, supported by growth in average revenue per occupied bed (ARPOB) and improved occupancy. ARPOB rose 8.4 per cent Y-o-Y to Rs 2.51 crore, while occupancy levels reached 69 per cent, compared to 66 per cent in Q4 FY24. Key specialties such as oncology and neurosciences reported revenue growth of 25 per cent and 19 per cent, respectively. International patient revenue grew 17 per cent Y-o-Y to Rs 145 crore in the quarter, contributing 8.1 per cent to overall hospital revenue, compared to 7.9 per cent in the same quarter last year. The diagnostics business reported subdued revenue growth of 3.5 per cent Y-o-Y, reaching Rs 306 crore. 'This comes after the company consolidated its stake in Agilus Diagnostics to 89.2 per cent by acquiring 31.52 per cent from private equity investors,' Fortis stated in its investor presentation. Commenting on the company's future plans, Ashutosh Raghuvanshi, managing director and chief executive officer, said Fortis will continue to actively pursue inorganic growth opportunities in its focus geographic clusters. 'Notable developments during the year included the successful acquisition of the 'Fortis' brand and trademarks, and our foray into Jalandhar through the signing of definitive agreements in February 2025 to acquire Shrimann Superspecialty Hospital,' he said. This acquisition will increase Fortis's capacity in Punjab from approximately 800 beds across four facilities to over 1,000 beds. In addition to Jalandhar, the company plans to add around 993 beds through brownfield projects at Manesar, Gurugram, Noida, Bengaluru (BG Road), and Faridabad. The company announced its results post market hours. On Tuesday, Fortis Healthcare shares closed 0.81 per cent lower at Rs 679.70 on the Bombay Stock Exchange (BSE).
